Pharma · Private company
Janssen Scientific Affairs, LLC
Track this companyFree. Adds Janssen Scientific Affairs, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- Other Biologic TherapiesCrohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- UstekinumabCrohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Guselkumab for Overlap Inflammatory Bowel Disease and SpondyloarthritisNOT_YET_RECRUITING · started May 20, 2026ClinicalTrials.gov NCT07602517 · fetched Nov 12, 2026
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaPHASE2 · RECRUITING · started Jun 5, 2025ClinicalTrials.gov NCT06461988 · fetched Nov 12, 2026
- Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab TherapyNA · RECRUITING · started Jun 1, 2025ClinicalTrials.gov NCT06586281 · fetched Nov 12, 2026
- Efficacy of Guselkumab in Treating Hailey Hailey DiseasePHASE2 · RECRUITING · started Mar 13, 2025ClinicalTrials.gov NCT06651489 · fetched Nov 12, 2026
- Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 1, 2025ClinicalTrials.gov NCT06563323 · fetched Nov 12, 2026
- Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal FailureEARLY_PHASE1 · RECRUITING · started Nov 1, 2024ClinicalTrials.gov NCT06142396 · fetched Nov 12, 2026
- Wellness & Workforce Solution for Lupus/Lupus NephritisNA · RECRUITING · started Sep 14, 2024ClinicalTrials.gov NCT06217107 · fetched Nov 12, 2026
- PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.PHASE3 · RECRUITING · started Sep 10, 2024ClinicalTrials.gov NCT06274047 · fetched Nov 12, 2026
- High-Risk Metachronous Oligometastatic Prostate Cancer TrialPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 17, 2024ClinicalTrials.gov NCT06212583 · fetched Nov 12, 2026
- Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE TrialPHASE2 · RECRUITING · started Mar 28, 2024ClinicalTrials.gov NCT06067269 · fetched Nov 12, 2026
- Sequential Therapy in Multiple Myeloma Guided by MRD AssessmentsPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 13, 2023ClinicalTrials.gov NCT05231629 · fetched Nov 12, 2026
- Guselkumab vs Golimumab in PsA TNF Inadequate Responder PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 14, 2023ClinicalTrials.gov NCT05669833 · fetched Nov 12, 2026
- Immune Spatial Features of Guselkumab Cutaneous ResponsePHASE4 · RECRUITING · started Jul 1, 2023ClinicalTrials.gov NCT05858632 · fetched Nov 12, 2026
- Precise Infliximab Exposure and Pharmacodynamic ControlPHASE2_PHASE3 · RECRUITING · started Jul 1, 2023ClinicalTrials.gov NCT05660746 · fetched Nov 12, 2026
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular AtherostenosisPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 2, 2022ClinicalTrials.gov NCT05047172 · fetched Nov 12, 2026
- Multi-Center PAMPA StudyPHASE4 · RECRUITING · started Feb 16, 2022ClinicalTrials.gov NCT05004727 · fetched Nov 12, 2026
- A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to DaratumumabPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 28, 2021ClinicalTrials.gov NCT04302324 · fetched Nov 12, 2026
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisRECRUITING · started Jun 24, 2021ClinicalTrials.gov NCT04372108 · fetched Nov 12, 2026
- A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 6, 2020ClinicalTrials.gov NCT04194554 · fetched Nov 12, 2026
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based TherapyPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 5, 2020ClinicalTrials.gov NCT04140162 · fetched Nov 12, 2026
- A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or LenalidomidePHASE2 · ACTIVE_NOT_RECRUITING · started Aug 28, 2020ClinicalTrials.gov NCT04497961 · fetched Nov 12, 2026
- Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started May 11, 2020ClinicalTrials.gov NCT04267887 · fetched Nov 12, 2026
- Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 13, 2019ClinicalTrials.gov NCT03500445 · fetched Nov 12, 2026
- Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 14, 2017ClinicalTrials.gov NCT03315026 · fetched Nov 12, 2026
- Psoriasis Longitudinal Assessment and RegistryACTIVE_NOT_RECRUITING · started Jun 21, 2007ClinicalTrials.gov NCT00508547 · fetched Nov 12, 2026